Cost Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Depending on the Quality of Warfarin Anticoagulation Control

The quality of oral anticoagulation in general practice in patients with atrial fibrillation

(2014) Sabrina Mueller et al.   European Journal of Internal Medicine

Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis

(2014) Carla Rognoni et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Expanding Role of Pharmacogenomics in the Management of Cardiovascular Disorders

(2013) Vincent Lai Ming Yip et al.   American Journal of Cardiovascular Drugs

Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS_2 Score: A Subgroup Analysis of the RE-LY Trial

(2013) Jonas Oldgren   ANNALS OF INTERNAL MEDICINE

Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation

(2013) James V. Freeman et al.   ANNALS OF INTERNAL MEDICINE

Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation

(2013) Anuraag R. Kansal et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing

(2013) Stephen E. Kimmel et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized Trial of Genotype-Guided Dosing of Warfarin

(2013) Munir Pirmohamed et al.   NEW ENGLAND JOURNAL OF MEDICINE

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants

(2013) Charalampos Kasmeridis et al.   PHARMACOECONOMICS

A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II)

(2012) Jeffrey L. Anderson et al.   CIRCULATION

Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries

(2012) Harriette G.C. Van Spall et al.   CIRCULATION

The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation

(2012) H. A. VAN DEN HAM et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF

(2012) Graeme J Hankey et al.   LANCET NEUROLOGY

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial

(2012) J Donald Easton et al.   LANCET NEUROLOGY

Cost–effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs

(2012) Talitha I Verhoef et al.   PHARMACOGENOMICS

Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes

(2011) Rebecca Howard et al.   CLINICA CHIMICA ACTA

Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA

(2011) M. Wieloch et al.   EUROPEAN HEART JOURNAL

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients

(2011) Arlene Gallagher et al.   THROMBOSIS AND HAEMOSTASIS

Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

(2010) et al.   EUROPEAN HEART JOURNAL

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

(2010) Lars Wallentin et al.   LANCET

Potential Clinical and Economic Outcomes of CYP2C9 and VKORC1 Genotype-Guided Dosing in Patients Starting Warfarin Therapy

(2009) J H S You et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Prognostic Value of the Modified Rankin Scale Score for Long-Term Survival after First-Ever Stroke

(2008) Krista F. Huybrechts et al.   CEREBROVASCULAR DISEASES

Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range

(2008) Stuart J. Connolly et al.   CIRCULATION